TrimetaziDine as a Performance-enhancING drug in Heart Failure with Preserved Ejection Fraction (DoPING-HFpEF): Rationale and design of a placebo-controlled cross-over intervention study.

被引：0
|
作者：
Van De Bovenkamp, A. A. [1 ]
Bakermans, A. J. [2 ]
Allaart, C. P. [1 ]
Nederveen, A. J. [2 ]
Kok, W. E. M. [3 ]
Van Rossum, A. C. [1 ]
Handoko, M. L. [1 ]
机构：
[1] Amsterdam UMC, Locat VUmc, Cardiol, Amsterdam, Netherlands
[2] Amsterdam UMC, Locat Acad Med Ctr, Radiol & Nucl Med, Amsterdam, Netherlands
[3] Amsterdam UMC, Locat Acad Med Ctr, Clin & Expt Cardiol, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P2022
引用
收藏
页码：357 / 357
页数：1
相关论文
共 36 条
  • [21] Safety and Efficacy of the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Heart Failure with Preserved Ejection Fraction (Capacity HFpEF): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
    Udelson, James E.
    Lewis, Gregory D.
    Shah, Sanjiv J.
    Zile, Michael R.
    Redfield, Margaret M.
    Burnett, John
    Parker, John D.
    Seferovic, Jelena
    Wilson, Phebe J.
    Mittleman, Robert S.
    Profy, Albert T.
    Konstam, Marvin A.
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S8 - S8
  • [22] Rehabilitation Enablement in Chronic Heart Failure - a facilitated self-care rehabilitation intervention in patients with heart failure with preserved ejection fraction (REACH-HFpEF) and their caregivers: rationale and protocol for a single-centre pilot randomised controlled trial
    Eyre, V.
    Lang, C. C.
    Smith, K.
    Jolly, K.
    Davis, R.
    Hayward, C.
    Wingham, J.
    Abraham, C.
    Green, C.
    Warren, F. C.
    Britten, N.
    Greaves, C. J.
    Doherty, P.
    Austin, J.
    Van Lingen, R.
    Singh, S.
    Buckingham, S.
    Paul, K.
    Taylor, R. S.
    Dalal, H. M.
    BMJ OPEN, 2016, 6 (10):
  • [23] Effect of breathing oxygen-enriched air on exercise performance in patients with pulmonary hypertension in heart failure with preserved ejection fraction. Randomized, placebo-controlled, crossover trial
    Muller, Julian
    Lichtblau, Mona
    Saxer, Stephanie
    Riccardo, Luigi-Riccardo
    Carta, Arcangelo F.
    Schneider, Simon R.
    Berlier, Charlotte
    Furian, Michael
    Bloch, Konrad E.
    Schwarz, Esther I.
    Ulrich, Silvia
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [24] Effect of Breathing Oxygen-Enriched Air on Exercise Performance in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction: A Randomized, Placebo-Controlled, Crossover Trial
    Mueller, Julian
    Lichtblau, Mona
    Saxer, Stephanie
    Calendo, Luigi-Riccardo
    Carta, Arcangelo F.
    Schneider, Simon R.
    Berlier, Charlotte
    Furian, Michael
    Bloch, Konrad E.
    Schwarz, Esther, I
    Ulrich, Silvia
    FRONTIERS IN MEDICINE, 2021, 8
  • [25] A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction-Design of Study TDE-HF-301
    Gomberg-Maitland, M.
    Frantz, R. P.
    Yehle, D.
    Deng, C.
    Shah, S. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [26] Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study
    Holmager, Pernille
    Schmidt, Ulla
    Mark, Peter
    Andersen, Ulrik
    Dominguez, Helena
    Raymond, Ilan
    Zerahn, Bo
    Nygaard, Birte
    Kistorp, Caroline
    Faber, Jens
    CLINICAL ENDOCRINOLOGY, 2015, 83 (06) : 931 - 937
  • [27] Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial 1c
    Davies, Melanie J.
    van der Meer, Peter
    Verma, Subodh
    Patel, Shachi
    Chinnakondepalli, Khaja M.
    Borlaug, Barry A.
    Butler, Javed
    Kitzman, Dalane W.
    Shah, Sanjiv J.
    Harring, Signe
    Salsali, Afshin
    Rasmussen, Soren
    von Lewinski, Dirk
    Abhayaratna, Walter
    Petrie, Mark C.
    Kosiborod, Mikhail N.
    LANCET DIABETES & ENDOCRINOLOGY, 2025, 13 (03): : 196 - 209
  • [28] A randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: the REACH-HFpEF Pilot Study (vol 8, e019649, 2018)
    Lang, C. C.
    Smith, K.
    Wingham, J.
    BMJ OPEN, 2019, 9 (03):
  • [29] Response to Letter Regarding Article, "Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure: A Double-Blind Placebo-Controlled Cross-Over Preliminary Study"
    Doehner, Wolfram
    Anker, Stefan D.
    Ogino, Kazuhide
    CIRCULATION-HEART FAILURE, 2010, 3 (03) : E14 - E14
  • [30] Letter by George Regarding Article, "Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure: A Double-Blind Placebo-Controlled Cross-Over Preliminary Study"
    George, Jacob
    CIRCULATION-HEART FAILURE, 2010, 3 (03) : E10 - E10
1234